drugset
drugset / Trial / NCT00395434

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

NCT00395434 ↗

Phase 1 Completed 20 enrolled Mateon Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.

Timeline

Start
2006-09
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject fosbretabulin Small molecule — Intravenous
Background Bevacizumab Monoclonal antibody — —

Indications

neoplasm